ECSP23012042A - Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este - Google Patents
Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de esteInfo
- Publication number
- ECSP23012042A ECSP23012042A ECSENADI202312042A ECDI202312042A ECSP23012042A EC SP23012042 A ECSP23012042 A EC SP23012042A EC SENADI202312042 A ECSENADI202312042 A EC SENADI202312042A EC DI202312042 A ECDI202312042 A EC DI202312042A EC SP23012042 A ECSP23012042 A EC SP23012042A
- Authority
- EC
- Ecuador
- Prior art keywords
- disubstituted
- steroid
- pyrazolyl
- methods
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Anesthesiology (AREA)
Abstract
Esta invención se refiere a un esteroide C21-pirazolilo 19-nor C3,3-disustituido de fórmula (I) y composiciones farmacéuticas de este. También se divulgan en el presente documento métodos para preparar las composiciones farmacéuticas del esteroide C21-pirazolilo 19-nor C3,3-disustituido de fórmula (I) y métodos de uso del esteroide C21-pirazolilo 19-nor C3,3-disustituido de fórmula (I) o formas sólidas cristalinas, sales farmacéuticamente aceptables y composiciones farmacéuticamente aceptables de este.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063054070P | 2020-07-20 | 2020-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP23012042A true ECSP23012042A (es) | 2023-03-31 |
Family
ID=77265332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202312042A ECSP23012042A (es) | 2020-07-20 | 2023-02-17 | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este |
Country Status (17)
Country | Link |
---|---|
US (2) | US20230285417A1 (es) |
EP (1) | EP4181884A1 (es) |
JP (1) | JP2023537240A (es) |
KR (1) | KR20230041049A (es) |
CN (1) | CN116367827A (es) |
AR (1) | AR123018A1 (es) |
AU (1) | AU2021312240A1 (es) |
BR (1) | BR112023000990A2 (es) |
CA (1) | CA3187178A1 (es) |
CL (1) | CL2023000176A1 (es) |
CO (1) | CO2023001579A2 (es) |
EC (1) | ECSP23012042A (es) |
IL (1) | IL299829A (es) |
MX (1) | MX2023000835A (es) |
PE (1) | PE20231301A1 (es) |
TW (1) | TW202220667A (es) |
WO (1) | WO2022020363A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ627781A (en) | 2012-01-23 | 2016-10-28 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
AR109393A1 (es) | 2016-08-23 | 2018-11-28 | Sage Therapeutics Inc | Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino |
JP2021505608A (ja) | 2017-12-08 | 2021-02-18 | セージ セラピューティクス, インコーポレイテッド | CNS障害を処置するためのジュウテリウム化された21−[4−シアノ−ピラゾール−1−イル]−19−ノル−プレガン−3.α−オール−20−オン誘導体 |
JP2024510436A (ja) | 2021-03-17 | 2024-03-07 | セージ セラピューティクス, インコーポレイテッド | 大うつ病性障害の処置のための19-ノルc3,3-2置換c21-n-ピラゾリルステロイド |
BR112023022264A2 (pt) | 2021-04-29 | 2024-01-23 | Sage Therapeutics Inc | Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo |
EP4329769A1 (en) | 2021-04-29 | 2024-03-06 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
AU2023220976A1 (en) | 2022-02-16 | 2024-09-05 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
WO2023163879A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
HUE041369T2 (hu) * | 2013-04-17 | 2019-05-28 | Sage Therapeutics Inc | 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására |
AR109393A1 (es) | 2016-08-23 | 2018-11-28 | Sage Therapeutics Inc | Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino |
WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
KR20210021005A (ko) * | 2018-06-12 | 2021-02-24 | 세이지 테라퓨틱스, 인크. | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
-
2021
- 2021-07-20 AU AU2021312240A patent/AU2021312240A1/en active Pending
- 2021-07-20 WO PCT/US2021/042394 patent/WO2022020363A1/en active Application Filing
- 2021-07-20 US US18/006,141 patent/US20230285417A1/en active Pending
- 2021-07-20 TW TW110126691A patent/TW202220667A/zh unknown
- 2021-07-20 IL IL299829A patent/IL299829A/en unknown
- 2021-07-20 CA CA3187178A patent/CA3187178A1/en active Pending
- 2021-07-20 JP JP2023504021A patent/JP2023537240A/ja active Pending
- 2021-07-20 BR BR112023000990A patent/BR112023000990A2/pt unknown
- 2021-07-20 KR KR1020237005548A patent/KR20230041049A/ko unknown
- 2021-07-20 EP EP21752441.2A patent/EP4181884A1/en active Pending
- 2021-07-20 PE PE2023000099A patent/PE20231301A1/es unknown
- 2021-07-20 AR ARP210102037A patent/AR123018A1/es unknown
- 2021-07-20 CN CN202180059412.0A patent/CN116367827A/zh active Pending
- 2021-07-20 MX MX2023000835A patent/MX2023000835A/es unknown
-
2022
- 2022-01-19 US US17/579,541 patent/US20230057130A1/en active Pending
-
2023
- 2023-01-19 CL CL2023000176A patent/CL2023000176A1/es unknown
- 2023-02-14 CO CONC2023/0001579A patent/CO2023001579A2/es unknown
- 2023-02-17 EC ECSENADI202312042A patent/ECSP23012042A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20231301A1 (es) | 2023-08-24 |
CO2023001579A2 (es) | 2023-03-07 |
WO2022020363A1 (en) | 2022-01-27 |
IL299829A (en) | 2023-03-01 |
KR20230041049A (ko) | 2023-03-23 |
MX2023000835A (es) | 2023-04-10 |
JP2023537240A (ja) | 2023-08-31 |
US20230285417A1 (en) | 2023-09-14 |
CN116367827A (zh) | 2023-06-30 |
BR112023000990A2 (pt) | 2023-03-28 |
US20230057130A1 (en) | 2023-02-23 |
EP4181884A1 (en) | 2023-05-24 |
WO2022020363A9 (en) | 2022-03-10 |
AU2021312240A1 (en) | 2023-02-02 |
CA3187178A1 (en) | 2022-01-27 |
TW202220667A (zh) | 2022-06-01 |
CL2023000176A1 (es) | 2023-09-15 |
AR123018A1 (es) | 2022-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP23012042A (es) | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este | |
CL2019003610A1 (es) | Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477). | |
ECSP20070854A (es) | Compuestos heteroaril tetracíclicos | |
ECSP22047876A (es) | Derivados de pirazolilo ?tiles como agentes anticancer?genos | |
CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
DOP2021000019A (es) | Inhibidores de inflamasoma nlrp3 | |
UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
ECSP19048759A (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, y proceso para producir el modulador | |
CO2022002634A2 (es) | Formas cristalinas de moduladores del cftr | |
UY38425A (es) | Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste | |
NI202000099A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
DOP2002000378A (es) | Derivados de pirazol para el tratamiento del vih | |
MX2020004283A (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
CL2022000955A1 (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
BR112023019435A2 (pt) | Inibidores de nek7 | |
AR119174A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
UY39390A (es) | Forma amorfa de un inhibidor de la malt1 y formulaciones del mismo | |
CY1126071T1 (el) | Φαρμακευτικα σκευασματα αναλογων κυκλοσπορινης | |
DOP2021000103A (es) | Pirazoles como moduladores de hemoglobina | |
CL2018002084A1 (es) | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1. |